Holen Sie sich die Stockscreener-App
0.489
0.00%
0.00
Schlusskurs vom Vortag:
$0.489
Offen:
$0.4899
24-Stunden-Volumen:
33,645
Relative Volume:
0.31
Marktkapitalisierung:
$5.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.28M
KGV:
-0.4699
EPS:
-1.0406
Netto-Cashflow:
$-4.80M
1W Leistung:
+1.73%
1M Leistung:
-17.13%
6M Leistung:
-30.15%
1J Leistung:
-54.17%
1-Tages-Spanne:
$0.48
$0.4985
1-Wochen-Bereich:
$0.48
$0.5198
52-Wochen-Spanne:
$0.4702
$1.51
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
Firmenname
Pharmacyte Biotech Inc
Sektor
Branche
Telefon
(917) 595.2850
Adresse
3960 HOWARD HUGHES PARKWAY, LAS VEGAS
Compare PMCB vs MOBBW, PSNYW, GOODO, SHMD, CHAD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 2.24 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.30 | 2.28B | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
4.29 | 773.76M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.37 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
3.355 | 220.96M | 52.15M | -21.46M | 0 | -0.4675 |
CHAD
Direxion Daily CSI 300 China A
|
8.06 | 197.39M | 0 | 0 | 0 | 0.00 |
Pharmacyte Biotech Inc Aktie (PMCB) Neueste Nachrichten
PharmaCyte Biotech Inc (PMCB) Key Financial Ratios – Valuation, Profitability & More - Value Research
PharmaCyte Biotech Inc (PMCB) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
PharmaCyte Biotech Inc (PMCB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
PharmaCyte Biotech (NASDAQ: PMCB): Why Is A scheduled reporting event in Focus Now? - Kalkine Media
PharmaCyte (PMCB) Financial Results: The Company Lists Its Latest Available Figures in the Current Update; Market Reaction: Shares Move 1.58% HigherQuarterly Profit Report - vinanet.vn
PMCB Q1 2026 Earnings: Clinical-Stage Biotech Posts -$0.09 EPS with No RevenueSegment Revenue Breakdown - vinanet.vn
PharmaCyte Biotech (PMCB) Climbs to $0.55 as Micro-Cap Biotech Holds Key SupportFundamentals - dars.gov.et
PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PharmaCyte Biotech Inc (PMCB) Stock News Today - TradingKey
PharmaCyte Biotech (PMCB) Holds Near $0.59 as Shares Dip 0.71%Change of Character - vinanet.vn
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Narrowing Loss Amid Clinical ProgressHealthcare Earnings Report - dars.gov.et
PharmaCyte Biotech, Inc. FY 2026: Revenue $0 Net income ($23.21M), EPS ($2.77) — 10-K Summary - TradingView
PharmaCyte Biotech Inc (PMCB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PharmaCyte Biotech Inc (PMCB) Institutional Confidence - TradingKey
PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PharmaCyte Biotech Inc (PMCB) Balance Sheet - TradingKey
PharmaCyte Biotech Inc (PMCB) Cash Flow - TradingKey
PharmaCyte Biotech Inc (PMCB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.600|Chg%:-0.005 - TradingKey
PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PharmaCyte Biotech Inc (PMCB) Valuation: PE, PB & Fair Value Analysis - TradingKey
PharmaCyte Biotech Inc (PMCB) Income Statement - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.576|Chg%:-0.024 - tradingkey.com
PMCB|PharmaCyte Biotech Inc|Price:0.611|Chg%:+0.035 - TradingKey
PharmaCyte Biotech (PMCB) Holds Near $0.57 Support Amid Minimal Price MovementSMA Signal - vinanet.vn
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Revenue-less Biotech Posts Net Loss; Stock SlipsEarnings Revision Report - vinanet.vn
PharmaCyte Biotech, Inc. Revenue Breakdown – NASDAQ:PMCB - TradingView
PharmaCyte Biotech Inc (PMCB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PharmaCyte Biotech (PMCB) Edges Lower Near Support; Key Levels in FocusLong Short Pair - vinanet.vn
PMCB Q1 2026 Earnings: Continued Development Costs Weigh on Results, No Revenue ReportedEarnings Season Outlook - vinanet.vn
PharmaCyte Biotech (PMCB) Slips 4% as Stock Tests Key Support Near $0.60Andrews Pitchfork - dars.gov.et
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director SCHECHTER JONATHAN - Moomoo
PharmaCyte Biotech (PMCB) Faces Near-Term Pressure, Testing Key Support at $0.60Tick Index - vinanet.vn
[Form 4/A] PharmaCyte Biotech, Inc. Amended Insider Trading Activity - Stock Titan
PharmaCyte Biotech (PMCB) cancels erroneous stock option grant - Stock Titan
PharmaCyte Biotech (PMCB) amends Form 4 to cancel option grant - Stock Titan
PharmaCyte Biotech (PMCB) director corrects erroneous, cancelled option grant - Stock Titan
PharmaCyte Biotech (PMCB) Slides 6.6% as Biotech Selling Pressure PersistsDebt Free Companies - dars.gov.et
PharmaCyte Biotech (PMCB) Slides 1.4% Near Key Support Level at $0.66Adaptive Moving Average - dars.gov.et
PharmaCyte Biotech (PMCB) Holds Near Support as Modest Decline Tests Trader ConvictionGap Down Bounce Plays - dars.gov.et
PMCB Q1 2026 Earnings: Losses Narrow as Biotech Advances Pipeline Amid Positive Market SentimentROA Comparison - Bölüm Sonu Canavarı
PharmaCyte Biotech | SCHEDULE 13G: Others - Moomoo
PMCB Q1 2026 Earnings: Loss Per Share of $0.09 as Clinical Pipeline AdvancesEarnings Quality Score - po-news-eg.net
PharmaCyte Biotech | DEF 14A: Definitive information statements - Moomoo
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Continued Pre‑Revenue Losses as Pipeline Development Drives Net LossEstimate Accuracy - dars.gov.et
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Slight Loss, Shares RiseEarnings Call Highlights - dars.gov.et
Price to book forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Price to sales forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Price to earnings forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Enterprise value to EBITDA forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Enterprise value to revenue forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Finanzdaten der Pharmacyte Biotech Inc-Aktie (PMCB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pharmacyte Biotech Inc-Aktie (PMCB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Silverman Joshua | CEO and President |
Jan 06 '26 |
Buy |
0.79 |
30,000 |
23,667 |
376,250 |
| Silverman Joshua | CEO and President |
Jan 05 '26 |
Buy |
0.78 |
30,000 |
23,493 |
346,250 |
| SCHECHTER JONATHAN | Director |
Jan 07 '26 |
Buy |
0.84 |
20,000 |
16,872 |
192,500 |
| SCHECHTER JONATHAN | Director |
Jan 06 '26 |
Buy |
0.79 |
20,000 |
15,808 |
172,500 |
| SCHECHTER JONATHAN | Director |
Jan 05 '26 |
Buy |
0.78 |
20,000 |
15,552 |
152,500 |
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):